Cargando…

Practical guidance for running late-phase platform protocols for clinical trials: lessons from experienced UK clinical trials units

BACKGROUND: Late-phase platform protocols (including basket, umbrella, multi-arm multi-stage (MAMS), and master protocols) are generally agreed to be more efficient than traditional two-arm clinical trial designs but are not extensively used. We have gathered the experience of running a number of su...

Descripción completa

Detalles Bibliográficos
Autores principales: Love, Sharon B., Cafferty, Fay, Snowdon, Claire, Carty, Karen, Savage, Joshua, Pallmann, Philip, McParland, Lucy, Brown, Louise, Masters, Lindsey, Schiavone, Francesca, Hague, Dominic, Townsend, Stephen, Amos, Claire, South, Annabelle, Sturgeon, Kate, Langley, Ruth, Maughan, Timothy, James, Nicholas, Hall, Emma, Kernaghan, Sarah, Bliss, Judith, Turner, Nick, Tutt, Andrew, Yap, Christina, Firth, Charlotte, Kong, Anthony, Mehanna, Hisham, Watts, Colin, Hills, Robert, Thomas, Ian, Copland, Mhairi, Bell, Sue, Sebag-Montefiore, David, Jones, Robert, Parmar, Mahesh K. B., Sydes, Matthew R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9449272/
https://www.ncbi.nlm.nih.gov/pubmed/36068599
http://dx.doi.org/10.1186/s13063-022-06680-4
_version_ 1784784258353594368
author Love, Sharon B.
Cafferty, Fay
Snowdon, Claire
Carty, Karen
Savage, Joshua
Pallmann, Philip
McParland, Lucy
Brown, Louise
Masters, Lindsey
Schiavone, Francesca
Hague, Dominic
Townsend, Stephen
Amos, Claire
South, Annabelle
Sturgeon, Kate
Langley, Ruth
Maughan, Timothy
James, Nicholas
Hall, Emma
Kernaghan, Sarah
Bliss, Judith
Turner, Nick
Tutt, Andrew
Yap, Christina
Firth, Charlotte
Kong, Anthony
Mehanna, Hisham
Watts, Colin
Hills, Robert
Thomas, Ian
Copland, Mhairi
Bell, Sue
Sebag-Montefiore, David
Jones, Robert
Parmar, Mahesh K. B.
Sydes, Matthew R.
author_facet Love, Sharon B.
Cafferty, Fay
Snowdon, Claire
Carty, Karen
Savage, Joshua
Pallmann, Philip
McParland, Lucy
Brown, Louise
Masters, Lindsey
Schiavone, Francesca
Hague, Dominic
Townsend, Stephen
Amos, Claire
South, Annabelle
Sturgeon, Kate
Langley, Ruth
Maughan, Timothy
James, Nicholas
Hall, Emma
Kernaghan, Sarah
Bliss, Judith
Turner, Nick
Tutt, Andrew
Yap, Christina
Firth, Charlotte
Kong, Anthony
Mehanna, Hisham
Watts, Colin
Hills, Robert
Thomas, Ian
Copland, Mhairi
Bell, Sue
Sebag-Montefiore, David
Jones, Robert
Parmar, Mahesh K. B.
Sydes, Matthew R.
author_sort Love, Sharon B.
collection PubMed
description BACKGROUND: Late-phase platform protocols (including basket, umbrella, multi-arm multi-stage (MAMS), and master protocols) are generally agreed to be more efficient than traditional two-arm clinical trial designs but are not extensively used. We have gathered the experience of running a number of successful platform protocols together to present some operational recommendations. METHODS: Representatives of six UK clinical trials units with experience in running late-phase platform protocols attended a 1-day meeting structured to discuss various practical aspects of running these trials. We report and give guidance on operational aspects which are either harder to implement compared to a traditional late-phase trial or are specific to platform protocols. RESULTS: We present a list of practical recommendations for trialists intending to design and conduct late-phase platform protocols. Our recommendations cover the entire life cycle of a platform trial: from protocol development, obtaining funding, and trial set-up, to a wide range of operational and regulatory aspects such as staffing, oversight, data handling, and data management, to the reporting of results, with a particular focus on communication with trial participants and stakeholders as well as public and patient involvement. DISCUSSION: Platform protocols enable many questions to be answered efficiently to the benefit of patients. Our practical lessons from running platform trials will support trial teams in learning how to run these trials more effectively and efficiently. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13063-022-06680-4.
format Online
Article
Text
id pubmed-9449272
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-94492722022-09-07 Practical guidance for running late-phase platform protocols for clinical trials: lessons from experienced UK clinical trials units Love, Sharon B. Cafferty, Fay Snowdon, Claire Carty, Karen Savage, Joshua Pallmann, Philip McParland, Lucy Brown, Louise Masters, Lindsey Schiavone, Francesca Hague, Dominic Townsend, Stephen Amos, Claire South, Annabelle Sturgeon, Kate Langley, Ruth Maughan, Timothy James, Nicholas Hall, Emma Kernaghan, Sarah Bliss, Judith Turner, Nick Tutt, Andrew Yap, Christina Firth, Charlotte Kong, Anthony Mehanna, Hisham Watts, Colin Hills, Robert Thomas, Ian Copland, Mhairi Bell, Sue Sebag-Montefiore, David Jones, Robert Parmar, Mahesh K. B. Sydes, Matthew R. Trials Methodology BACKGROUND: Late-phase platform protocols (including basket, umbrella, multi-arm multi-stage (MAMS), and master protocols) are generally agreed to be more efficient than traditional two-arm clinical trial designs but are not extensively used. We have gathered the experience of running a number of successful platform protocols together to present some operational recommendations. METHODS: Representatives of six UK clinical trials units with experience in running late-phase platform protocols attended a 1-day meeting structured to discuss various practical aspects of running these trials. We report and give guidance on operational aspects which are either harder to implement compared to a traditional late-phase trial or are specific to platform protocols. RESULTS: We present a list of practical recommendations for trialists intending to design and conduct late-phase platform protocols. Our recommendations cover the entire life cycle of a platform trial: from protocol development, obtaining funding, and trial set-up, to a wide range of operational and regulatory aspects such as staffing, oversight, data handling, and data management, to the reporting of results, with a particular focus on communication with trial participants and stakeholders as well as public and patient involvement. DISCUSSION: Platform protocols enable many questions to be answered efficiently to the benefit of patients. Our practical lessons from running platform trials will support trial teams in learning how to run these trials more effectively and efficiently. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13063-022-06680-4. BioMed Central 2022-09-06 /pmc/articles/PMC9449272/ /pubmed/36068599 http://dx.doi.org/10.1186/s13063-022-06680-4 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Methodology
Love, Sharon B.
Cafferty, Fay
Snowdon, Claire
Carty, Karen
Savage, Joshua
Pallmann, Philip
McParland, Lucy
Brown, Louise
Masters, Lindsey
Schiavone, Francesca
Hague, Dominic
Townsend, Stephen
Amos, Claire
South, Annabelle
Sturgeon, Kate
Langley, Ruth
Maughan, Timothy
James, Nicholas
Hall, Emma
Kernaghan, Sarah
Bliss, Judith
Turner, Nick
Tutt, Andrew
Yap, Christina
Firth, Charlotte
Kong, Anthony
Mehanna, Hisham
Watts, Colin
Hills, Robert
Thomas, Ian
Copland, Mhairi
Bell, Sue
Sebag-Montefiore, David
Jones, Robert
Parmar, Mahesh K. B.
Sydes, Matthew R.
Practical guidance for running late-phase platform protocols for clinical trials: lessons from experienced UK clinical trials units
title Practical guidance for running late-phase platform protocols for clinical trials: lessons from experienced UK clinical trials units
title_full Practical guidance for running late-phase platform protocols for clinical trials: lessons from experienced UK clinical trials units
title_fullStr Practical guidance for running late-phase platform protocols for clinical trials: lessons from experienced UK clinical trials units
title_full_unstemmed Practical guidance for running late-phase platform protocols for clinical trials: lessons from experienced UK clinical trials units
title_short Practical guidance for running late-phase platform protocols for clinical trials: lessons from experienced UK clinical trials units
title_sort practical guidance for running late-phase platform protocols for clinical trials: lessons from experienced uk clinical trials units
topic Methodology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9449272/
https://www.ncbi.nlm.nih.gov/pubmed/36068599
http://dx.doi.org/10.1186/s13063-022-06680-4
work_keys_str_mv AT lovesharonb practicalguidanceforrunninglatephaseplatformprotocolsforclinicaltrialslessonsfromexperiencedukclinicaltrialsunits
AT caffertyfay practicalguidanceforrunninglatephaseplatformprotocolsforclinicaltrialslessonsfromexperiencedukclinicaltrialsunits
AT snowdonclaire practicalguidanceforrunninglatephaseplatformprotocolsforclinicaltrialslessonsfromexperiencedukclinicaltrialsunits
AT cartykaren practicalguidanceforrunninglatephaseplatformprotocolsforclinicaltrialslessonsfromexperiencedukclinicaltrialsunits
AT savagejoshua practicalguidanceforrunninglatephaseplatformprotocolsforclinicaltrialslessonsfromexperiencedukclinicaltrialsunits
AT pallmannphilip practicalguidanceforrunninglatephaseplatformprotocolsforclinicaltrialslessonsfromexperiencedukclinicaltrialsunits
AT mcparlandlucy practicalguidanceforrunninglatephaseplatformprotocolsforclinicaltrialslessonsfromexperiencedukclinicaltrialsunits
AT brownlouise practicalguidanceforrunninglatephaseplatformprotocolsforclinicaltrialslessonsfromexperiencedukclinicaltrialsunits
AT masterslindsey practicalguidanceforrunninglatephaseplatformprotocolsforclinicaltrialslessonsfromexperiencedukclinicaltrialsunits
AT schiavonefrancesca practicalguidanceforrunninglatephaseplatformprotocolsforclinicaltrialslessonsfromexperiencedukclinicaltrialsunits
AT haguedominic practicalguidanceforrunninglatephaseplatformprotocolsforclinicaltrialslessonsfromexperiencedukclinicaltrialsunits
AT townsendstephen practicalguidanceforrunninglatephaseplatformprotocolsforclinicaltrialslessonsfromexperiencedukclinicaltrialsunits
AT amosclaire practicalguidanceforrunninglatephaseplatformprotocolsforclinicaltrialslessonsfromexperiencedukclinicaltrialsunits
AT southannabelle practicalguidanceforrunninglatephaseplatformprotocolsforclinicaltrialslessonsfromexperiencedukclinicaltrialsunits
AT sturgeonkate practicalguidanceforrunninglatephaseplatformprotocolsforclinicaltrialslessonsfromexperiencedukclinicaltrialsunits
AT langleyruth practicalguidanceforrunninglatephaseplatformprotocolsforclinicaltrialslessonsfromexperiencedukclinicaltrialsunits
AT maughantimothy practicalguidanceforrunninglatephaseplatformprotocolsforclinicaltrialslessonsfromexperiencedukclinicaltrialsunits
AT jamesnicholas practicalguidanceforrunninglatephaseplatformprotocolsforclinicaltrialslessonsfromexperiencedukclinicaltrialsunits
AT hallemma practicalguidanceforrunninglatephaseplatformprotocolsforclinicaltrialslessonsfromexperiencedukclinicaltrialsunits
AT kernaghansarah practicalguidanceforrunninglatephaseplatformprotocolsforclinicaltrialslessonsfromexperiencedukclinicaltrialsunits
AT blissjudith practicalguidanceforrunninglatephaseplatformprotocolsforclinicaltrialslessonsfromexperiencedukclinicaltrialsunits
AT turnernick practicalguidanceforrunninglatephaseplatformprotocolsforclinicaltrialslessonsfromexperiencedukclinicaltrialsunits
AT tuttandrew practicalguidanceforrunninglatephaseplatformprotocolsforclinicaltrialslessonsfromexperiencedukclinicaltrialsunits
AT yapchristina practicalguidanceforrunninglatephaseplatformprotocolsforclinicaltrialslessonsfromexperiencedukclinicaltrialsunits
AT firthcharlotte practicalguidanceforrunninglatephaseplatformprotocolsforclinicaltrialslessonsfromexperiencedukclinicaltrialsunits
AT konganthony practicalguidanceforrunninglatephaseplatformprotocolsforclinicaltrialslessonsfromexperiencedukclinicaltrialsunits
AT mehannahisham practicalguidanceforrunninglatephaseplatformprotocolsforclinicaltrialslessonsfromexperiencedukclinicaltrialsunits
AT wattscolin practicalguidanceforrunninglatephaseplatformprotocolsforclinicaltrialslessonsfromexperiencedukclinicaltrialsunits
AT hillsrobert practicalguidanceforrunninglatephaseplatformprotocolsforclinicaltrialslessonsfromexperiencedukclinicaltrialsunits
AT thomasian practicalguidanceforrunninglatephaseplatformprotocolsforclinicaltrialslessonsfromexperiencedukclinicaltrialsunits
AT coplandmhairi practicalguidanceforrunninglatephaseplatformprotocolsforclinicaltrialslessonsfromexperiencedukclinicaltrialsunits
AT bellsue practicalguidanceforrunninglatephaseplatformprotocolsforclinicaltrialslessonsfromexperiencedukclinicaltrialsunits
AT sebagmontefioredavid practicalguidanceforrunninglatephaseplatformprotocolsforclinicaltrialslessonsfromexperiencedukclinicaltrialsunits
AT jonesrobert practicalguidanceforrunninglatephaseplatformprotocolsforclinicaltrialslessonsfromexperiencedukclinicaltrialsunits
AT parmarmaheshkb practicalguidanceforrunninglatephaseplatformprotocolsforclinicaltrialslessonsfromexperiencedukclinicaltrialsunits
AT sydesmatthewr practicalguidanceforrunninglatephaseplatformprotocolsforclinicaltrialslessonsfromexperiencedukclinicaltrialsunits